Pith. sign in

REVIEW 4 major objections 5 minor 42 references

Molecular-Size Control of Properties of Therapeutic Nano-Paper Allows for Selective Drug Storage in Small Doses

T0 review · 4 major / 5 minor · reviewed 2026-08-04 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read The paper claims that its therapeutic nano-paper—a nanoscale weave of cellulose and peptide hydrogel—stores hydrophilic drugs in the cellulose domains, lipophilic drugs in the peptide mesh, and adapts its structure around each drug for low-

desk verdict A promising materials proof-of-principle that overreaches on therapeutic claims; the structural observations are worth a careful referee, but the selective-storage story is underdetermined. read the letter →

arxiv 2509.08019 v1 pith:WBJW2N7W submitted 2025-09-09 physics.med-ph cond-mat.mtrl-sciphysics.bio-ph

Elisabeth Erbes , Naireeta Biswas , Calvin J. Gavilett , Matthias Schwartzkopf , Krishnayan Basuroy , Qing Chen , Andrei Chumakov , Susann Frenzke
show 14 more authors
Marc Gensch Korneliya Goordeyeva Patrycja Kielb Sonja Kirchner Volker Körstgens Peter Müller-Buschbaum Henrike M. Müller-Werkmeister Jan Rubeck Sreevidya Thekku Veedu Jose de Jesus Velazquez-Garcia Vivian Waclawek Daniel Söderberg Stephan V. Roth Simone Techert
This is my paper · ORCID
classification physics.med-phcond-mat.mtrl-sciphysics.bio-ph
keywords therapeuticnano-paperdrugdeliverynanocellulosepeptidehydrogelGISAXS/GIMAXSlipophilicitylow-dosestoragein-situX-rayscattering
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper introduces 'therapeutic nano-paper' (TNP), a film built from alternating nanoscale layers of carboxy-methylated cellulose and a peptide hydrogel, and claims it can hold hydrophilic and lipophilic drugs simultaneously, each in the domain that matches its solubility. Using in-situ, time-resolved X-ray scattering while drug solutions are sprayed onto the growing film, the authors find that the most hydrophilic drug studied (camostat mesylate) swells the cellulose fiber domains, while progressively more lipophilic drugs (chloroquine phosphate, remdesivir) progressively swell the fractal peptide mesh. These structural responses track the drugs' published lipophilicity values (logD7.4 and protein binding), and the film's formation kinetics differ by drug, with hydrophilic loading triggering an autocatalytic reorganization of both networks and lipophilic loading enriching the peptide mesh. If correct, a single carrier material could be matched to whichever drug a treatment requires and deliver it in small, precisely controlled doses—relevant for potent drugs whose overdose risk demands low-dose control.

What carries the argument

The central object is therapeutic nano-paper (TNP): a nano-stacked, interwoven template of carboxy-methylated cellulose (CMC) fibers and a peptide hydrogel (P) whose long chains, including hydrophobic glycine-lysine-phenylalanine-glycine (GLFG) stretches among hydrophilic residues, form a micellar fractal mesh. This adjacent pairing of a hydrophilic cellulose phase and a lipophilic peptide phase is what gives drug molecules of complementary solubility a matching domain. The argument rests on two scattering observables from grazing-incidence X-ray data: the cellulose fiber-aggregate radii (approximately 150 nm and 50 nm unloaded) from the small-angle regime, and the peptide mesh's 'fractal ra

What would settle it

A cross-sectional chemical map of a drug-loaded TNP film (for example Raman or element-specific microscopy) plus a sequential release assay that extracts the cellulose and peptide domains separately would settle where the drugs actually reside. If the hydrophilic drug were found outside the cellulose domains, or the lipophilic drug outside the peptide mesh, the domain-selective storage claim would collapse.

Watch

Extended reading notes

Core claim

The paper's central claim is that its therapeutic nano-paper adapts around each drug: hydrophilic drugs are stored in the cellulose domains, lipophilic drugs in the peptide mesh. Hydrophilic camostat mesylate swells the large cellulose fibers from 150 to 280 nm radius (medium fibers from 50 to 200 nm); lipophilic chloroquine phosphate and remdesivir leave cellulose nearly unchanged and instead swell the peptide fractal radius from 0.47 to 0.74 and 1.22 nm. Spray-fabrication kinetics are drug-specific: hydrophilic loading autocatalytically reorganizes both networks; lipophilic loading enriches the peptide mesh. FTIR shows the peptide beta-sheet structure survives loading. The authors conclude

Load-bearing premise

The load-bearing assumption is that the scattering-visible swelling of a nanoscale domain really means the drug molecules are stored inside that domain; the paper presents no direct chemical mapping, spectroscopic localization, or release data that would rule out drugs sitting on the film surface or in separate crystalline phases.

Editorial extensions

If this is right

  • Hydrophilic and lipophilic drugs can be loaded into the same carrier without chemical modification, each partitioning into the domain matching its solubility.
  • Dose can be controlled at the nanoscale by tuning drug concentration and domain sizes during spray fabrication, addressing the overdose risk of potent drugs.
  • The peptide mesh's fractal radius responds to molecular size as well as lipophilicity (0.47 to 1.22 nm across the studied drugs), implying the carrier can be tuned for a range of drug sizes, not just solubility classes.
  • Because structural response correlates with published logD7.4 and protein-binding values, a drug's expected storage compartment could be predicted from tables before any experiment.
  • Each drug has a characteristic embedding half-time (20-62 s in the studied spray cycles), so fabrication parameters can be chosen per drug to avoid incomplete loading or precipitation.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • A direct test the paper does not make: measuring release profiles from the two compartments separately, or chemically mapping drug position inside the film, would confirm the compartment assignment that the scattering analysis infers.
  • The authors' conclusion that TNP can be customized for 'all type of drugs' goes beyond the studied set of model drugs; it is a generalization from a proof-of-principle, not a demonstrated universal.
  • If domain-selective uptake holds, a natural extension is co-loading two drugs of opposite solubility into the two subphases at once—a combination therapy in a single patch—which the paper motivates but does not demonstrate.
  • The logD7.4 and protein-binding correlations suggest a quantitative prediction rule: given a drug's tabulated lipophilicity, one could anticipate whether it will swell the cellulose domain or the peptide mesh before running the scattering experiment.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 5 minor

Summary. The paper introduces a 'therapeutic nano-paper' (TNP) made of interwoven carboxymethylated cellulose (CMC) and peptide hydrogel (P) domains, and claims that this architecture can selectively store hydrophilic drugs in CMC domains and lipophilic drugs in the peptide mesh. The authors use in-situ, time-resolved GISAXS/GIMAXS during spray deposition of several drugs (CM, CQP, RD, NM) to extract domain radii (R_CMC1, R_CMC2, R_P), correlation lengths, and kinetic intensity traces. They correlate these structural parameters with externally tabulated logD7.4 and protein-binding values, and supplement the X-ray work with FTIR and DFT-computed molecular radii. The conclusion is that TNP is an 'ideal carrier platform' for all drug types, enabling low-dose controlled and site-specific release.

Significance. If the central claims were fully substantiated, the TNP concept could be a useful platform for personalized, low-dose drug delivery, and the combination of in-situ scattering with external lipophilicity data is attractive. The manuscript has genuine strengths: the GISAXS/GIMAXS experiments are time-resolved and in-situ, stated errors are provided for many fitted parameters, FTIR serves as a secondary structural probe, and the DFT radii and logD7.4/protein-binding data are independent of the scattering model. These features reduce (though do not eliminate) concerns about circularity. However, the paper's headline conclusions—selective compartment storage, autocatalytic embedding kinetics, and universal carrier suitability—are considerably broader than what the current evidence can support.

major comments (4)
  1. [Results and Discussion, Figs. 2C and 3G; Conclusions, final paragraph] The central claim that hydrophilic drugs are stored in CMC domains and lipophilic drugs in the peptide mesh rests entirely on changes in fitted scattering radii (R_CMC1, R_CMC2, R_P). No direct chemical mapping, element-specific spectroscopy, or release/dissolution experiment verifies that the drugs are molecularly dispersed inside the intended compartments. Equivalent scattering changes could arise from surface adsorption, drug-rich crystalline/amorphous aggregates, drying-induced matrix reorganization, or film-thickness/roughness effects. The statement after Fig. 2C that 'The big changes in the GISAXS and GIMAXS data prove a significant embedding of the drugs into the TNP' overstates what scattering alone can prove. The authors should either add direct localization and release/loading measurements, or substantially temper the 'ideal carrier platform for all type of drugs' conclusion.
  2. [Fig. 5 and following bullet list; Conclusion, first paragraph] The 'autocatalytic' kinetic interpretation is not supported by the data as presented. The analysis shows normalized intensity decreases/increases of the CMC2 and P regions, but no kinetic model, rate law, or concentration-dependence test is given. The conclusion that 'the autocatalytic embedding of CM in TNP is unequivocally supported' is unjustified; a classical first-order or simple two-step process would produce similar normalized intensity traces. The authors should fit competing kinetic models with meaningful uncertainties or remove the autocatalytic claim.
  3. [Fig. 4 and accompanying text] The correlations between structural parameters and logD7.4/protein binding are based on at most four drugs (CM, CQP, RD, NM). No correlation coefficients, confidence intervals, or goodness-of-fit measures are reported. Some fitted values overlap within their stated errors (e.g., R_CMC1 = 200 ± 15 nm for CQP vs 190 ± 20 nm for RD), so the claimed monotonic trend in Fig. 4A is not robust. Given that the 'generalizable' conclusion depends on these correlations, a larger drug set and statistical treatment are needed, or the claims must be limited to the studied compounds.
  4. [Results and Discussion, two-step analysis and SI Tables S3/S4] The structural interpretation depends on the two-step cylinder/fractal fitting scheme, but the fitting details are relegated to SI Tables S3/S4, which were not available for review. Model uniqueness, parameter correlations, and fit quality cannot be checked. Since the domain-selective storage story relies on these fitted radii, the authors should provide the full fitting protocol, including parameter uncertainties and model comparison, either in the main text or in a reviewable supplement. The brief description of 'Int0' and 'Int1' in Fig. 3 is also insufficient for reproducibility.
minor comments (5)
  1. [Fig. 3F caption] The caption says 'RM' but the text and context indicate 'RD' (Remdesivir). Please correct.
  2. [Bullet list after Fig. 5] The sentence 'This relocation of the P-assembled structures to other areas within the TNP implies that the disordered arms of the P-mesh loosen their network between the fibres and compactly arrange themselves with the drugs around the fibres.' appears twice verbatim. Remove the duplicate.
  3. [Throughout] Define all drug abbreviations (CM, CQP, RD, NM) and give the full peptide sequence in the main text or a clear appendix footnote; the current 'foodnote' reference is incomplete.
  4. [Abstract and Conclusions] The phrase 'site-specific drug release on a beyond-nanomolar scale' and 'low-dose-controlled consumption' imply functional release data that are not presented. Please rephrase as potential or future work unless release measurements are added.
  5. [Fig. 4 and text] The terms 'radii of gyration', 'fractal radius R_P', and 'aggregate radii R_CMC1/R_CMC2' are used somewhat interchangeably. Clarify the exact definitions and which quantity is plotted in each panel.

Circularity Check

0 steps flagged · score 2.0 of 10

No significant circularity; minor methodological self-citations are not load-bearing.

full rationale

The paper's derivation chain is: (1) fabricate TNP with chemically defined hydrophilic CMC and lipophilic peptide (P) domains; (2) measure GISAXS/GIMAXS and fit structural parameters (R_CMC1, R_CMC2, R_P, xi_P) to scattering models; (3) correlate these fitted parameters with external drug properties (logD7.4, protein binding) and DFT-computed molecular radii; (4) interpret the correlations as selective drug partitioning. No step defines a predicted quantity in terms of the same fitted input. The fractal analysis method is cited from prior work by the same authors (refs 31-33), but this is a methodological citation, not an unverified uniqueness claim; the external correlations and DFT calculations provide independent benchmarks. The absence of direct chemical mapping of drug location is an evidence limitation, not circularity. The self-citations to prior methodological work are minor and not load-bearing, so the circularity score is low.

Assumptions & free parameters 8 free parameters · 5 assumptions · 0 invented entities

The paper introduces a new material architecture but no new theoretical entity. Its central claims rest on structural parameters fitted to X-ray scattering data, on tabulated lipophilicity values treated as external inputs, and on several modeling assumptions about how the scattering maps to drug location.

free parameters (8)
  • R_CMC1 = 150±10 nm (pure); 280±25 nm (with CM)
    Large cellulose aggregate radius from cylinder-fit GISAXS; central to the swelling claim.
  • R_CMC2 = 50±5 nm (pure); 200±18 nm (with CM)
    Middle-sized cellulose aggregate radius from GISAXS.
  • d_CMC1 and d_CMC2 = listed in SI Table S3
    Inter-fiber distances from GISAXS refinement.
  • R_P = 0.471±0.001 nm (TNP) to 1.22±0.06 nm (RD)
    Fractal subunit radius of the peptide network from GIMAXS; key observable for drug-size correlation.
  • ξ_P = not tabulated in main text; decreases from RD to CM to CQP
    Correlation length of the fractal peptide domains.
  • fractal dimension of P-network = not reported in main text
    Additional parameter in the fractal GIMAXS model.
  • EIAS particle center-to-center distance = 5±0.5 nm for pure P-network
    Used as an inter-peptide distance scale in the fractal analysis.
  • kinetic half-times τ1/2 = 35±2 s to 62±5 s depending on drug and domain
    Fitted time constants from normalized GISAXS intensity traces.
assumptions (5)
  • domain assumption Cylinder/prolate model adequately represents CMC aggregates in the q-range 0.02-0.1 nm^-1
    Used for GISAXS refinement; if wrong, radii R_CMC1 and R_CMC2 are not physical.
  • domain assumption Fractal model from refs 31-34 describes the P-network in the q-range 0.1-1.2 nm^-1
    Underlies R_P and ξ_P, the central structural observables.
  • domain assumption DFT gas-phase molecular radii approximate drug sizes inside the dry matrix
    Used to assign drug size ordering; no condensed-phase calculations are presented.
  • domain assumption Tabulated logD7.4 and protein-binding values represent drug solubility behavior in the dried CMC/P matrix
    The correlations in Fig. 4 depend on this transfer from aqueous/pharmaceutical databases to the solid nano-paper.
  • domain assumption Spray deposition results in equilibrium embedding rather than surface crystallization
    No direct imaging or spectroscopy verifies that drugs are inside the intended compartments.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Molecular-Size Control of Properties of Therapeutic Nano-Paper Allows for Selective Drug Storage in Small Doses." pith.science (2026). https://pith.science/paper/WBJW2N7W

@misc{pith2026250908019,
  author       = {Pith},
  title        = {Pith review of: Molecular-Size Control of Properties of Therapeutic Nano-Paper Allows for Selective Drug Storage in Small Doses},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/WBJW2N7W}},
  note         = {Machine review of arXiv:2509.08019}
}
read the original abstract

A novel concept of nano-scaled interwoven templates for drug delivery with alternating hydro- and lipophilicity properties is introduced. They are built from cellulose and peptide hydrogel in tandem, and characterized by a nano-stacked interwoven design, thus enabling for tuning the lipophilicity in the mesh nano-domains in which drug candidates of complementary lipophilicities can be embedded. This allows for low-dose-controlled consumption and therapeutic applications. Time-resolved and in-situ grazing incidence X-ray scattering studies confirm the design of the therapeutic nano-paper and create conditions suitable for the drug storage of complementary properties. The molecular design has the potential of a locally controlled, site-specific drug release on a beyond-nanomolar scale. Generalized, the design may contribute to facile developments of personalized medicine.

Figures

Figures reproduced from arXiv: 2509.08019 by the authors.

Figure 3
Figure 3. Representation of the structural adaptation of TNP for three representative drugs of this study: Camostat Mesylate (CM), Chloroquine-Phosphate (CQP), and Remdesevir (RD): (A) GISAXS refinement of the CMC network for embedded CM, (B) GIMAXS refinement of the fractal P-network for the embedded CM drug; (C) GISAXS refinement of the CMC network for embedded CQP (it additionally shows a substructure formation at qy = 0.0… view at source ↗
Figure 4
Figure 4. Correlation between the structural analysis of the drug [PITH_FULL_IMAGE:figures/full_fig_p007_4.png] view at source ↗
Figure 5
Figure 5. In-situ kinetic and structural analysis of the drug embedding during the spray production of the TNP. All three TNP formations are kinetically driven. The insets present the final TNP-drug structures and morphologies after the last spraying cycle with CMC structures in blue, smaller dots for peptides and larger dots for the drugs. (A) For CM, a decomposition of the 50nm-middle-sized, fiber-shaped CMC aggregates (blu… view at source ↗

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

42 extracted references · 41 canonical work pages

  1. [1]

    F. S. Collins, H. Varmus, A new initiative on precision medicine. N. Engl. J. Med. 372 (9), 793-795 (2015). doi:10.1056/NEJMp1500523

    work page doi:10.1056/nejmp1500523 2015

  2. [2]

    SOLIDARITY list

    Cambridge MedChem Consulting CC BY 3.0 (2019) . https://pubchem.ncbi.nlm.nih.gov/bioassay/19424; “SOLIDARITY list”, WHO Reports (2020- 2022). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research- on-novel-coronavirus-2019-ncov/covid-19-technology-access-pool/solidarity-call-to-action; National Center for Biotechnology Informatio...

    work page 2019

  3. [3]

    Felton Ed., Pharmceuticals Press, Royal Pharmaceutical Society (2023)

    Remington Essentials of Pharmaceutics, 21th Edition, L. Felton Ed., Pharmceuticals Press, Royal Pharmaceutical Society (2023)

    work page 2023

  4. [4]

    Hoffmann, H

    M. Hoffmann, H. Kleine -Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, T. S. Schiergens, G. Herrler, W. H. Wu, A. Nitsche, M. A. Müller, C. Drosten, S. Pöhlmann, SARS- CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically -proven protease inhibitor. Cell 181(2), 271-280 (2020)

    work page 2020

  5. [5]

    Uno, Camostat mesilate therapy for COVID -19

    Y. Uno, Camostat mesilate therapy for COVID -19. Intern Emerg. Med. 15, 1577–1578 (2020). doi: 10.1007/s11739-020-02345-9

    work page doi:10.1007/s11739-020-02345-9 2020

  6. [6]

    Yamamoto, S

    M. Yamamoto, S. Matsuyama, X. Li, M. Takeda, Y. Kawaguchi, J -I. Inoue, Z. Matsuda, Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob. Agents Chemother. 60, 6532–6539 (2016). doi:10.1128/AAC.01043-16

    work page doi:10.1128/aac.01043-16 2016

  7. [7]

    Hoffmann, S

    M. Hoffmann, S. Schroeder, H. Kleine -Weber, M. A. Müller, C. Drosten, S. Pöhlmann, Nafamostat mesylate blocks activation of SARS -CoV-2: new treatment option for COVID. Antimicrob. Agents Chemother. 64 (6), e00754-20 (2020). doi: 10.1128/AAC.00754-20

    work page doi:10.1128/aac.00754-20 2020

  8. [8]

    M. Wang, R. Cao, I. Zhang, X. Yang, J. Liu, Z. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019- nCoV) in vitro. Cell. Res. 30, 269–271 (2020). doi:10.1038/s41422-020-0282-0

    work page doi:10.1038/s41422-020-0282-0 2019

Show all 42 references
  1. [9]

    Hoffmann, K

    M. Hoffmann, K. Mösbauer, H. Hofmann -Winkler, A. Kaul, H. Kleine -Weber, N. Krüger, N. C. Gassen, M. A. Müller, C. Drosten, S. Pöhlmann, Chloroquine does not inhibit SARS - CoV-2 infection of human lung cells. Nature 585, 588-590 (2020)

    2020

  2. [10]

    F. J. Frost, H. Petersen, K. Tollestrup, B. Skipper, Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 131(4), 1006-12 (2007)

    2007

  3. [11]

    Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Yao, Zhao, B. Zhang, X. Li, L. Zhang, Y. Duan1, J. Yu, L.in Wang, K. Yang, F. Liu, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. Guddat, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao, H. Yang, Structure -based drug design, virtual sc...

    2020 doi

  4. [12]

    He ttinga, R

    J. He ttinga, R. Carlisle, Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects, Vaccines 8 (3), 534 (2020). doi: 10.3390/vaccines8030534

    2020 doi

  5. [13]

    In alphabetical order, the named drugs range from (serine) protease inhibitors as Camostat Mesylate (CM) or Nafamostat Mesylate (NM) (7-10) through (non -specific) inflammatory TLR7-9 inhibitors, as Hydroxychloroquine Sulfate, ATM activators, such as Chloro quine Diphosphate (...

  6. [14]

    Zhang, N

    D. Zhang, N. Wang, Q. Liu, W. Bai, Y. Guo, Z. Chen, B. Liao, G. Huang, S. Pan, K. Ma, Y. Zheng, H. Wang, L. Huang, R. You, Y. -Q. Guan, Functionalized Nanopolyaniline/Fibrin Gel Composite Scaffolds: Implication s for the Treatment of Cardiovascular Disease, ACS Appl. Nano Mat....

    2023 doi

  7. [15]

    Håkansson, A

    K. Håkansson, A. Fall, F. Lundell, S. Yu, C. Krywka, S. V. Roth, G. Santoro, M. Kvick, L. P. Wittberg, L. Wågberg, L. D. Söderberg, Hydrodynamic alignment and assembly of nanofibrils resulting in strong cellulose filaments, Nat. Commun. 5 (1), 1-10 (2014)

    2014

  8. [16]

    C. J. Brett, N. Mittal, W. Ohm, M. Gensch, L. P. Kreuzer, V. K örstgens, M. Månsson, H. Frielinghaus, P. M üller-Buschbaum, L.D. S öderberg, S. V. Roth, Water -induced structural rearrangements on the nanoscale in ultrathin nanocellulose films, Macromolecules 52, 4721- 4724...

    2019 doi

  9. [18]

    Petri, S

    M. Petri, S. Frey, A. Menzel, D. Görlich, S. Techert, Structural characterization of nanoscale meshworks within a Nucleoporin FG hydrogel, Biomacromolec.13 (6), 1882-1889 (2012). doi: 10.1021/bm300412q

    2012 doi

  10. [19]

    T. V. Patil, D. K. Patel, S. Deb Dutta, K. Ganguly, T. Subhra Santra, K. Lim, Nanocellulose, a versatile platform: From the delivery of active molecules to tissue engineering applications, Bioact. Mat. 9, 566-589 (2022)

    2022

  11. [20]

    Abitbol, A

    T. Abitbol, A. Rivkin, Y. Cao, Y. Nevo, E. Abraham, T. Ben-Shalom, S. Lapidot, O. Shoseyov, Nanocellulose, a tiny fiber with huge applications, Curr. Op. Biotechnol. 39, 76-88 (2016)

    2016

  12. [21]

    S. Bari, R. Boll, K. Idzik, K. Kubiček, D. Raiser, S. Thekku Veedu, Z. Yin, S. Techert, Chpt. Ultrafast time structure imprints in complex chemical and biochemical reactions, eds. U. Bergmann, V. Yachandra, J. Yano, Fundamentals and application of free-electron lasers, Royal C...

    2017 doi

  13. [22]

    Velazquez -Garcia, K

    J. Velazquez -Garcia, K. Basuroy, D. Storozhuk, J. Wong, S. Demeshko, F. Meyer, R. Henning, S. Techert, Short- vs Long-range Elastic Distortion: Structural Dynamics of a [2x2] Tetrairon(II) Spin Crossover Grid Complex Observed by Time -Resolved X -Ray Crystallography, Dalt. Tr...

    2022 doi

  14. [23]

    Buffet, A

    A. Buffet, A. Rothki rch, R. Döhrmann, V. Körstgens, M. Kashem, J. Perlich, G. Herzog, M. Schwartzkopf, R. Gehrke, P. Müller -Buschbaum, S. V. Roth, P03 - the microfocus and nanofocus X-ray scattering (MiNaXS) beamline of the PETRA III storage ring: the microfocus endstation, ...

    2012

  15. [24]

    Zhang, G

    P. Zhang, G. Santoro, S. Yu, S. K. Vayalil, S. Bommel, S. V. Roth, Manipulating the assembly of spray -deposited nanocolloids: in -situ study and monolayer film preparation, Langmuir 32, 4251-4255 (2016)

    2016

  16. [25]

    Benecke, W

    G. Benecke, W. Wagermaier, C. Li, M. Schwartzkopf, G. Flucke, R. Hoerth, I. Zizak, M. Burghammer, E. Metwalli, P. Müller-Buschbaum, M. Trebbin, S. Förster, O. Paris, S. V. Roth, P. Fratzl, A customizable software for fast reduction and analysis of large X-ray scattering data s...

    2014

  17. [26]

    C. J. Schaffer, C. M. Palumbiny, M. A. Niedermeier, C. Jendrzejewski , G. Santoro, S. V. Roth, and P. Müller -Buschbaum: A direct evidence of morphological degradation on a nanometer scale in polymer solar cells, Adv. Mater. 25, 6760-6764 (2013)

    2013

  18. [27]

    H. Yang, S. Yang, J. Kong, A. Dong, S. Yu, Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy, Nat. Prot. 10, 382–396 (2015). doi:10.1038/nprot.2015.024

    2015 doi

  19. [28]

    M. Wang, L. Xu, H. Hu, M. Zhai, J. Peng, Y. Nho, J. Li, Radiation synthesis of PVP/CMC hydrogels as wound dressing, Nuclear Instruments and Methods in Physics B 265 (1), 385-389 (2007). doi: 10.1016/j.nimb.2007.09.009

    2007 doi

  20. [29]

    Pengfei M

    L. Pengfei M. Zhai, L. Jiuqiang P. Peng, W. Jilan, Radiation preparation and swelling behavior of sodium carboxymethyl cellulose hydrogels, Rad. Phys. Chem. 63 (3–6) 525-528 (2002). https://doi.org/10.1016/S0969-806X(01)00649-1

    2002 doi

  21. [30]

    5(5), 1653-6 (2004)

    T Aliferis, H Iatrou, N Hadjichristidis, Living polypeptides, Biomacromol. 5(5), 1653-6 (2004). doi: 10.1021/bm0497217

    2004 doi

  22. [31]

    Quevedo, M

    W. Quevedo, M. Petri, G. Busse , S. Techert, On the Mechanism of Photo -induced Phase Transitions in Ternary Liquid Crystal Systems Near Thermal Equilibrium, J. Chem. Phys. 129, 024502-1-10 (2008). doi: 10.1063/1.2943200

    2008 doi

  23. [32]

    Petri, A

    M. Petri, A. Menzel, O. Bunk, G. Busse, S. Techert, Concentration Effects on the Dynamics of Liquid Crystalline Self-Assembly: Time-Resolved X-ray Scattering Studies, J. Phys. Chem. A 115, 2176–2183 (2011). doi: 10.1021/jp1108224

    2011 doi

  24. [33]

    Quevedo, G

    W. Quevedo, G. Busse, J. Hallm ann, R. More, M. Petri, F. Krasniqi, A. Rudenko, Th. Tschentscher, A. Foehlisch, A. Pietsch, M. Beye, N. Stojanovic, S. Düsterer, R. Treusch, M. Tolkiehn, K. Mann, C. Peth, S. Techert, I. Rajkovic, Ultrafast Time Dynamics Studies of Periodic Latt...

    2012 doi

  25. [34]

    Doucet et al

    M. Doucet et al. SasView Version 5.0.3 and references therein. http://doi.org/10.5281/zenodo.3930098

    doi

  26. [35]

    Ruelle and U

    P. Ruelle and U. W. Kesselring, The hydrophobic effect - a key ingredient in predicting n-octanol-water partition coefficients, J. Pharm. Sci. 87 (8), 1015 (1998)

    1998

  27. [36]

    R. A. Pierotti, Chem. Rev. 76, 717 –726.23 (1976); J. C. Dearden and G.M. Bresnen, Thermodynamics of water -octanol and wate r-cyclohexane partitioning of some aromatic compounds, Int. J. Mol. Sci. 6, 119-129 (2005)

    1976

  28. [37]

    https://pubchem.ncbi.nlm.nih.gov/bioassay/19424; Cambridge MedChem Consulting CC BY 3.0 (2019)

    2019

  29. [38]

    K. T. Savjani, A. K. Gajjar, J. K. Savjani, Drug Solubility: Importance and Enhancement Techniques, ISRN Pharmaceutics (2012). doi: 10.5402/2012/195727

    2012 doi

  30. [39]

    M. C. Wenlock , R. P. Austin , P. Barton , A. M. Davis , P. D. Leeson, A comparison of physicochemical property profiles of development and marketed oral drugs, J. Med. Chem. 46, 1250-1256 (2003)

    2003

  31. [40]

    J. A. Arnot, S. L. Planey, The influence of lipophilicity in drug discovery and design. Exp. Opin. Drug Discov. 7(10), 863-875 (2012). doi: 10.1517/17460441.2012.714363

    2012

  32. [41]

    M. J. Waring, Lipophilicity in drug discovery, Exp. Opin. Drug Discov. 5(3), 235-48 (2010). doi: 10.1517/17460441003605098

    2010 doi

  33. [42]

    Lobo, Is there enough focus on lipophilicity in drug discovery?, Exp

    S. Lobo, Is there enough focus on lipophilicity in drug discovery?, Exp. Opin. Drug Discov. 15(3), 261-263 (2020). doi:10.1080/17460441.2020.1691995

    2020

  34. [43]

    Investigation of processes for spraying and spray-coating of hybrid cellulose -based nanostructures

    V. Pliška, B. Testa, Dr. H. vd Waterbeemd, Lipophilicity in Drug Action and Toxicology, Book Series: Methods and Principles in Medicinal Chemistry, VCH Verlagsgesellschaft mbH (1996), ISBN:9783527293834, Online ISBN:9783527614998 doi: 10.1002/9783527614998 Acknowledgments: Fun...

    1996 doi

Pith tools

Reviewed August 4, 2026 · model on record in the stance chip above.